目的:評價電腦肝病治療儀治療病毒性肝炎的療效及不良反應。方法:將116例病毒性肝炎患者隨機分為治療組及對照組,治療組60例,對照組56例。兩組均以抗炎、保肝、降酶、退黃、對癥為治則。治療組加用電腦肝病儀治療，每日一次。結果:治療組在消化道癥狀改善方面有效率950%,黃疸消退方面有效率902%。谷丙轉氨酶恢復方面有效率85%。而對照組分別為8214%、6786%和7143%。結論:電腦肝病治療儀治療肝病能迅速改善消化道癥狀,有效降低黃疸、轉氨酶,未見明顯不良反應。
目的 觀察茵陳柴平湯治療重度慢性乙型肝炎的療效及不良反應。 方法 2009年3月－2010年3月，選擇采用茵陳柴平湯聯合常規保肝藥物治療50例重度慢性乙型肝炎患者（治療組），并與50例僅用常規保肝藥物治療的重度慢性乙型肝炎患者（對照組）進行比較，觀察治療2、4周時的臨床癥狀、肝功能及凝血酶原活動度等指標的變化。 結果 治療2、4周時，治療組在肝功能及凝血酶原活動度等指標均有顯著改善，無嚴重不良反應；4周時，治療組的癥狀緩解率（84%）明顯高于對照組（66%）；其總有效率（96%）亦高于對照組（80%）。 結論 茵陳柴平湯治療重度慢性乙型肝炎具有較好的臨床療效，且無嚴重不良反應。
Objective To observe the eotaxin expression of rat airway smooth muscle cells ( ASMCs) induced by serum from asthmatic rats, and explore the possible mechanism. Methods ASMCs isolated fromrat tracheas were cultured in vivo. Then they were treated with serum from asthmatic rats, or treated with serum and dexamethasone simultaneously. The level of eotaxin protein in supernatant and eotaxin mRNA in ASMCs were measured by ELISA and reverse transcription-polymerase chain reaction. The expression of cAMP in ASMCs was examined by radioimmunoassay. Results After the treatment with sensitized serum, the eotaxin level in supernatant and mRNA expression in ASMCs were significantly higher [ ( 107. 09 ±7. 12) ng/L vs. ( 0. 63 ±0. 56) ng/L, P lt; 0. 05; 1. 39 ±0. 04 vs. 0. 05 ±0. 01, P lt;0. 05] , and the level of cAMP in ASMCs was significantly lower compared with the control group [ ( 17. 58 ±3. 62) ng/L vs. ( 32. 39 ±3. 36) ng/L, P lt; 0. 05] . After intervened by the sensitized serum and dexamethasone simultaneously, the protein and mRNA expressions of eotaxin were lower compared with those intervened by sensitized serumalone [ ( 64. 18 ±4. 04) ng/L and 0. 77 ±0. 19] . The level of eotaxin in supernatant was negatively correlated with cAMP level in ASMCs ( r = - 0. 788, P lt; 0. 01) . Conclusions There is anautocrine function in ASMCs as inflammatory cells after stimulation with sensitized serum. Eotaxin may play an important roll in the pathogenesis of asthma via a cAMP-dependent pathway.
ObjectiveTo understand the role of metformin on reducing incidence of type 2 diabetes mellitus (T2MD) patients complicated with liver cancer. MethodThe related literatures of metformin treated patients with T2MD complicated with liver cancer at home and abroad in recent years were reviewed. ResultsA large number of epidemiological and clinical data showed that the metformin might prevent the occurrence of the T2MD patients complicated with liver cancer, its mechanism was mainly inhibited the proliferation of hepatoma cells through the ATM-LKB1-AMPK-mTOR pathway, PI3K/Akt/mTOR pathway, or miRNA. The current controversy was the authenticity of the data, the influencing factors included the aging problem and characteristics of metformin user. The prospective study design rigorous remained to be clarified. ConclusionMetformin could reduce the incidence of T2MD patients complicated with liver cancer, and could inhibit the growth of liver cancer cells, which provides a new way of thinking for the comprehensive treatment of liver cancer.